Effect of addition of anti-inflammatory medication to anti-depressant medication on C-reactive protein levels in the treatment of depression

Professor Bernhard Baune0 个研究点目标入组 122 人开始时间: 2017年4月11日最近更新: 2021年6月7日

适应症

试验速览

暂无简介。

•1. The study participant is willing and able to provide informed consent.
•2. Age 18 – 75 years of age.
•3. Diagnosis of a Major Depressive Episode (MDE) as part of Major Depressive Disorder (MDD), using DSM-5 criteria.
•4. Montgomery Asberg Depression Rating Scale (MADRS) score greater than or equal to 26 at screening visit and baseline.
•5. Duration of the current MDE is at least 3 months.
•6. Use of a previous treatment in at least one prior episode of depression

•1. Presence of a co-morbid psychiatric disorder other than MDD that is a focus of clinical concern as confirmed by the Mini International Neuropsychiatric Interview (MINI).
•2. A known relevant inflammatory or immune-related disorder such as rheumatoid arthritis, colitis, clinically significant asthma, multiple sclerosis, SLE, acute infections or fever.
•3. A known neurodegenerative disease
•4. Any medication for a general medical disorder that may affect cognitive function
•5. Electroconvulsive therapy (ECT) within the last 6 months.
•6. The study participant has reported having received investigational agents as part of a separate study within 30 days of the screening visit.
•7. Contraindications to the study drugs

发起方

Professor Bernhard Baune